NASDAQ-NMS:ITCI

Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode

Retrieved on: 
Wednesday, March 15, 2023
Brain, GLP, Biogen, Roche, NOT, Intraparenchymal hemorrhage, Advertising, MCI, Human, Parkinson's disease, COVID-19, Disease, CSF, Agitation, Dementia, Rat, Security (finance), Doctor of Philosophy, AD, Dog, Fast Track, MRI, RBC Capital Markets, Caffeine, Bleeding, Amyloid, Communication, A2A, The Company, Marvel, Mayo Clinic, Research, Form 10-K, Depression, Clinical professor, Risk, DSM-IV codes, CT, Patient, Annual report, MIQ, FDA, Diagnosis, Safety, News, BIIB, FNM, Toxicology, Immunotherapy, SL, Biotechnology, OTC, Pharmaceutical industry, Medical imaging, Alzheimer's disease, Istradefylline

VANCOUVER, B.C., March 15, 2023 /PRNewswire/ -- March 15, 2023 - USA News Group - According to a 2022 study of more than 6 million patients 65 and older, the risk factor for developing Alzheimer's disease increases by 50-80% in older adults who caught COVID-19. With Statista stating nearly 11.5 million COVID-19 cases of people over 65 years old as of November 23, 2022, and the Alzheimer's Association forecasting global dementia cases to triple by 2050, society is about to get hit with a tsunami of this devastating disease. Thankfully the biotech sector is working diligently to try and combat this coming onslaught of Alzheimer's and dementia, through new diagnostic methods and treatments, including work from companies such as Marvel Biosciences Corp. (TSXV:MRVL), Biogen Inc. (NASDAQ:BIIB), Prothena Corporation plc (NASDAQ:PRTA), Intra-Cellular Therapies (NASDAQ:ITCI), and Roche Holding AG (OTC:RHHBY).

Key Points: 
  • In the case of Marvel Biosciences Corp. (TSXV:MRVL), the biotech company is moving forward with its lead asset MB-204 in targeting Alzheimer's and depression .
  • MB-204 is a novel fluorinated derivative of Istradefylline, the only clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease.
  • Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving mood and concentration.
  • MB-204 will be highly disruptive to the existing market and, we believe, will be a welcomed therapy for patients who suffer from Alzheimer's Disease and Depression.